Sofetabart Mipitecan

Eli Lilly is pushing sofetabart mipitecan (LY4170156), a folate receptor alpha (FRα) antibody-drug conjugate carrying an exatecan (topoisomerase 1 inhibitor) payload, into Phase 3 ovarian cancer with the FRAmework-01 trial (NCT07213804) [1]. The study runs in two parts: Part A as monotherapy in platinum-resistant disease (cancer that progressed within 6 months of completing platinum-based chemotherapy, the current backbone of ovarian cancer treatment), where AbbVie's Elahere (mirvetuximab soravtansine) already owns the FRα-positive niche [2][3], and Part B in combination with bevacizumab in platinum-sensitive disease (recurrence more than 6 months after completing platinum) [1]. The platinum-sensitive arm is the real commercial prize because that population is several times larger than platinum-resistant - global estimates run roughly 3-4x - and is currently treated with platinum re-induction plus bevacizumab or PARP inhibitors. Sofetabart already has FDA Breakthrough Therapy designation in platinum-resistant ovarian cancer after Phase 1 (NCT06400472) showed a 50% ORR in 104 evaluable patients, including responses in post-Elahere patients [5][12]. Lilly's oncology business sits a distant fourth behind diabetes, obesity, and immunology in its $65.2B 2025 revenue base [4]; a successful ovarian cancer ADC would meaningfully reshape the therapeutic mix and signal Lilly's intent to be a real oncology player beyond Verzenio. Elahere generated ~$690M globally in 2025 [13] - the commercial baseline sofetabart must clear to matter.

Sofetabart mipitecan is a novel compound, never approved anywhere, in Phase 3 for ovarian, fallopian tube, and peritoneal cancers via FRAmework-01 (NCT07213804), enrollment target ~1080, recruiting at 200+ sites globally [1]. Parallel Phase 1 dose-finding work continues in NCT06400472 across selected advanced solid tumors with an enrollment target of 495 [5]. FDA granted Breakthrough Therapy designation in mid-2026 for adult platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received prior bevacizumab and mirvetuximab soravtansine [12]. The asset carries Lilly's LY4170156 development code, indicating in-house discovery rather than acquisition. The INN suffix '-tecan' identifies the payload as a camptothecin-class topoisomerase 1 inhibitor; specifically, sofetabart uses exatecan tethered via Lilly's proprietary cleavable polysarcosine linker (PSARlink) to an Fc-silent humanized anti-FRα monoclonal antibody [12]. This puts sofetabart in the same payload family as AstraZeneca/Daiichi Sankyo's Enhertu (deruxtecan, also exatecan-derived) and Gilead's Trodelvy (SN-38) rather than the maytansinoid payload (DM4) that Elahere uses. Primary PFS readout for Part A (platinum-resistant monotherapy) is likely 2027 to 2028 given recruiting status and trial size; Part B (platinum-sensitive plus bevacizumab) PFS will follow later because that population has longer event-free intervals. Drug-to-antibody ratio (DAR) has not been publicly disclosed by Lilly.

FRα is a protein stuck on the surface of most ovarian cancer cells [6]. Its job in healthy biology is grabbing folate (vitamin B9) from the bloodstream and pulling it inside the cell, where folate is used as raw material for DNA synthesis. Ovarian, fallopian tube, and peritoneal tumors crank up FRα production because rapidly dividing cells need a lot of folate. Open Targets evidence scores FRα against ovarian cancer at 0.484 and against fallopian tube and peritoneal neoplasms at similar levels [7]. Healthy adult tissues barely express FRα outside the kidney's proximal tubule and a few epithelial surfaces, which is what makes the receptor usable as a homing beacon for targeted therapy. An antibody-drug conjugate is mechanically a bomb on a guided missile: an anti-FRα antibody finds the tumor cell, the cell internalizes the antibody-receptor complex, the linker chemistry cleaves inside the cell, and the topoisomerase 1 inhibitor payload breaks the DNA-copying machinery during cell division. The mechanism is well-validated by mirvetuximab soravtansine (Elahere), which won full FDA approval in March 2024 for FRα-high platinum-resistant ovarian cancer based on the MIRASOL Phase 3 trial showing PFS and OS benefit over investigator's choice chemotherapy [3][8]. Where sofetabart could differentiate is the payload class: camptothecin-class warheads like exatecan are membrane-permeable after release, producing a 'bystander killing' effect where the payload can diffuse from a target-expressing cell into neighboring cells that express little or no FRα. Elahere's maytansinoid DM4 is largely membrane-impermeable and lacks meaningful bystander activity. In heterogeneous FRα-expressing tumors - which dominate the platinum-sensitive population and the lower-expressing platinum-resistant subset - bystander killing is a plausible mechanistic basis for sofetabart to work in patients where Elahere does not. The Phase 1 finding that sofetabart drove responses across all FRα expression levels including post-Elahere patients [12] is consistent with this hypothesis. Target biology risk here is low; differentiation risk is moderate, not high, given the early evidence.

FRAmework-01 (NCT07213804) is a two-part Phase 3, n≈1080, currently recruiting at 200+ global sites [1]. Part A enrolls platinum-resistant high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer for sofetabart monotherapy versus investigator's choice chemotherapy. Part B enrolls platinum-sensitive disease and tests sofetabart plus bevacizumab against a control regimen [1]. Primary endpoint is progression-free survival. Running both populations under one protocol is efficient on operations but introduces design complexity: different comparators, different expected event rates, and the platinum-sensitive arm carries genuinely unresolved biology because no FRα ADC has yet beaten platinum-based regimens in head-to-head Phase 3. Importantly, ImmunoGen/AbbVie's PICCOLO Phase 2 of mirvetuximab in FRα-high platinum-sensitive recurrent ovarian cancer DID meet its ORR primary endpoint at 51.9% (95% CI 40.4-63.3%), with median PFS 6.93 months and median OS 27.17 months [9]. PICCOLO was a single-arm study and so cannot replace platinum re-induction without a randomized comparison, but it removed the question of whether FRα ADCs work at all in platinum-sensitive disease - they do. Lilly is betting Part B can convert a positive single-arm signal into a randomized Phase 3 win, this time as a platinum-bevacizumab combination rather than a chemotherapy replacement. FRα expression cutoff is the patient-selection lever that determines both effect size and addressable market size. Elahere requires at least 75% of tumor cells staining 2+ for FRα; sofetabart's Phase 1 response across all FRα expression levels suggests Lilly may use a less restrictive cutoff. An n=1080 commitment is large but defensible given that Phase 1 ORR data (50% in 104 patients [12]) and FDA Breakthrough Therapy designation [12] de-risk the asset substantially relative to a typical Phase 3.

The model gives this drug a 39% chance of eventually being approved. That figure starts from a historical baseline of about 48% for Phase 3 drugs in this area, then shifts based on ten specific facts about the trial and sponsor. The estimate rises because the trial has more secondary endpoints than usual, uses open-label or light blinding, and enrolled more patients than is typical for this phase - but falls because earlier-phase results were weak or limited. The remaining factors were close to average for this stage, so they didn't move the number much either way.

Efficacy in platinum-sensitive disease is the biggest unknown. PICCOLO showed mirvetuximab works in PSOC at single-arm Phase 2 (ORR 51.9%) [9], but no FRα ADC has won a randomized Phase 3 against a platinum-based comparator. Lilly is betting that sofetabart plus bevacizumab beats the standard platinum-based regimen - a higher bar than displacing chemotherapy in platinum-resistant disease. The FRα expression cutoff is a non-trivial design lever: set the bar too low and effect size dilutes, set it too high and the addressable market shrinks; Phase 1 cross-expression activity gives Lilly room to choose a less restrictive cutoff than Elahere's ≥75%, which would expand the addressable population. Safety: topoisomerase 1 payloads (exatecan, DXd, SN-38) carry interstitial lung disease (ILD) signals across the class, with Enhertu carrying a black-box ILD warning and multiple ADC programs having been paused for pneumonitis events. Ocular toxicity is the other class-defining signature for FRα ADCs - Elahere's MIRASOL data forced dose modifications for corneal events [3]. Payload chemistry differences between exatecan and Elahere's DM4 may shift the side-effect profile but will not eliminate either ocular or pulmonary risk. Execution risk: n=1080 across two populations stretches the trial, and platinum-sensitive recurrent disease is a less captured population at recurrence, which can slow enrollment. Commercial: even with approval, payers will compare against Elahere (2025 global sales ~$690M [13], projected to ~$2.6B by 2032) on cost-effectiveness, and Lilly needs a clear differentiation story - better efficacy across the FRα spectrum, better tolerability, or a platinum-sensitive combination label that Elahere does not have. Competitive density: BAT8006 from Bio-Thera Solutions [14] could reach the platinum-resistant market in China and possibly emerging markets ahead of or alongside sofetabart, putting downward pressure on global pricing.

Worth watching closely - moved up from 'interesting' to 'important' by Phase 1 readout and Breakthrough Therapy designation. Part A (platinum-resistant) is now de-risked enough by the 50% Phase 1 ORR [12] that even a derivative win against Elahere should land; the question is differentiation magnitude. Part B (platinum-sensitive plus bevacizumab) is the asymmetric opportunity: a clean Phase 3 win there opens a market segment several times the size of platinum-resistant, and PICCOLO's positive single-arm signal [9] de-risks the biology if not the comparator design. The data points that matter next: (1) Part A interim ORR/PFS to confirm Phase 1-to-Phase 3 translation; (2) Bio-Thera BAT8006 Phase 3 readout timing and FRα-spectrum strategy [14], because that defines competitive ceiling on global pricing; (3) any payload-class ILD signal across the broader exatecan/DXd ADC space. Check ASCO and ESMO 2026-2027 for further Phase 1 expansion data and track Lilly's earnings calls [11] for pipeline updates. Lilly's $65.2B 2025 revenue base [4] means this asset is portfolio diversification rather than a make-or-break bet, which paradoxically increases the chance the program runs cleanly to completion rather than being pruned for cash. Total addressable market for a successful Part B win is large: platinum-sensitive ovarian cancer recurrence covers most of the recurrent ovarian cancer population, multiple lines deep - Elahere consensus 2032 sales of $2.6B [13] is the lower bound benchmark; a platinum-sensitive label that Elahere does not have plus payload differentiation could support meaningfully larger peak sales for sofetabart over a similar time horizon.